Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

• Sponsor: H. Lee Moffitt Cancer Center and Research Institute (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT01005745
• Collaborator: (none)
• Enrollment: 19
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 164.3
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

The overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Melanoma	Procedure: Surgery; Drug: Administration of Lymphodepletion; Other: Adoptive Cell Transfer; Drug: High Dose IL-2	N/A

Detailed Description

Patients are being offered admission to this study to test the side effects of an investigational treatment prepared from special immune cells (T cells) specific for melanoma. A T-cell is a type of lymphocyte. Lymphocytes are a type of white blood cell that protect people from viral infections; help other cells fight bacterial and fungal infections; produce antibodies; fight cancers; and coordinate the activities of other cells in the immune system. These special immune cells will be taken from a sample of the patient's tumor tissue that will be surgically removed from their body and grown in the laboratory. They will then given back to the patient in their veins. These cells are called tumor infiltrating lymphocytes (TIL). We wish to study the side effects of TIL when they are given with two chemotherapy drugs to temporarily decrease the patient's own immune cells and a drug called Interleukin-2 (IL-2). The two chemotherapy drugs called fludarabine and cytoxan are used to greatly reduce the number of normal lymphocytes circulating in the patient's body, called lymphodepletion, so that there will be more "space" for the cancer fighting lymphocytes (T-cells) that will be infused in their veins. We wish to find out how often these cells can shrink or slow the growth of the patient's melanoma. We also wish to find out the effects of lymphodepletion followed by TIL and high dose IL-2 on the patient's immune system. The lymphodepletion followed by TIL and high dose IL-2 is experimental, and has not been proven to help treat melanoma.

The IL-2 has been approved by the Food and Drug Administration (FDA) for the treatment of metastatic melanoma that cannot be surgically removed. The chemotherapy drugs cytoxan and fludarabine used for lymphodepletion have been approved by the FDA, but not for the treatment of metastatic melanoma.

The combination of lymphodepletion followed by TIL and high dose IL-2 is not FDA approved but the FDA is permitting its use in this study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 19 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
• Actual Study Start Date: Oct 20, 2009
• Actual Primary Completion Date: Jan 31, 2014
• Anticipated Study Completion Date: Jul 1, 2023

Arms and Interventions

Arm

Intervention/Treatment

Experimental: TIL With High Dose IL-2 Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion.

Procedure: Surgery; Surgery to remove a tumor for growth of TIL; Other Names: Tumor Infiltrating Lymphocytes (TIL) T-cell lymphocyte ; Drug: Administration of Lymphodepletion; Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo; Other Names: Cytoxan ; Other: Adoptive Cell Transfer; T-cell infusion; Drug: High Dose IL-2; Beginning approximately 12 - 16 hours after cell infusion.; Other Names: Interleukin-2 Aldesleukin Proleukin

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Tumor Infiltrating Lymphocytes (TIL) Growth [192 Days Post Surgical Resection]

   Feasibility was the primary endpoint of this trial, defined as a patient who can grow and expand T-cells: Number of participants with fragments cultured; Number of participants with fragments that reached a final count of 20e6 cells within 5 weeks of culture; Number of participants with fragments that reached a final count of 20e6 cells within 5 weeks of culture and were cocultured with autologous or human leukocyte antigen (HLA)-matched tumor cells for interferon(IFN)-γ production; Number of participants with fragments that produced IFN-γ in response to autologous or HLA-matched tumor cells.

Secondary Outcome Measures

1. Number of Participants With Objective Response (OR) [Average of 10 Months Follow-up]

   OR is defined as the patient being alive at Day 70 and tumor size evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be a complete response or partial response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Evaluations were made by computed tomography (CT) scan approximately 6 to 8 weeks after the cell infusion, or CT scan approximately 10 weeks after the cell infusion, or by clinical evaluation during the first 70 days.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease.

• Residual measurable disease after resection of target lesion(s) for TIL growth

• Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 -1. ECOG performance status of 0-1 will be inferred if the patient's level of energy is ≥ 50% of baseline.

• Patients may be treatment-naïve or may have been previously treated for metastatic disease.

• Patients with a negative pregnancy test (urine or serum) must be documented at screening for women of childbearing potential (WOCBP).

• Adequate renal, hepatic and hematologic function, including creatinine of less than or equal to 1.7 gm/dL, total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL, aspartic transaminase (AST) and alanine transaminase (ALT) of less than 3X institutional upper limit of normal (ULN), hemoglobin of 8 gm/dL or more, white blood count (WBC) of 3000 per mm³ and total granulocytes of 1000 per mm³ or more, and platelets of 100,000 per mm³ or more.

• Patients must have a positive screening Epstein-Barr virus (EBV) antibody titre on screening test.

• Patients with antibiotic allergies per se are not excluded; although the production of TIL for adoptive transfer includes antibiotics, extensive washing after harvest will minimize systemic exposure to antibiotics.

• Patients that had previously grown sterile, validated TIL under Good Manufacturing Practices (GMP) conditions on Moffitt Clinical trial protocol 15375 (Use of Excess Melanoma Tumor Specimens Not Required for Diagnostic Purposes for Validation of Tumor Infiltrating Lymphocyte [TIL] Growth Procedures) meeting the above criteria may be consented and enrolled in the current trial using the previously established TIL stored in the Cell therapies Core facility for up to 2 years.

• At screening, patients with ≤ 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated).

• At screening, patients with CNS metastases treated with either surgical resection and/or radiation therapy may be included. Patients may be included if the largest lesion is ≤ 1 cm, and there is no evidence of progressive CNS disease on brain imaging at least 28 days after treatment.

• At screening, patients may be included if the largest lesion is > 1 cm or > 3 in number, and there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy.

• All laboratory and imaging studies must be completed and satisfactory within 30 days of signing the consent document.

Exclusion Criteria:

• Patients with active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system are excluded.

• Patients testing positive for human immunodeficiency virus (HIV) titre, Hepatitis B surface antigen, Hepatitis C antibody, Human T-lymphotropic virus (HTLV) I or II antibody, or both rapid plasma reagent (RPR) and fluorescein treponemal antibodies (FTA) positive are excluded.

• Patients who are pregnant or nursing

• Patients needing chronic, immunosuppressive systemic steroids

• Patients with autoimmune diseases that require immunosuppressive medications

• Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated

• Patients with > 3 untreated CNS metastases or evidence of peri-tumoral edema will be excluded.

• Patients with ≤ 3 untreated CNS metastases but with at least one lesion >1 cm or peri-tumoral edema will be excluded.

• Patients with treated CNS metastases > 1 cm or > 3 in number will be excluded if there is evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy.

• Inability to comprehend and give informed consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	United States	33612

Sponsors and Collaborators

• H. Lee Moffitt Cancer Center and Research Institute

Investigators

• Principal Investigator: Amod Sarnaik, M.D., H. Lee Moffitt Cancer Center and Research Institute

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Moffitt Cancer Center Clinical Trials website

Publications

None provided.

• Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
• ClinicalTrials.gov Identifier: NCT01005745
• Other Study ID Numbers: MCC-15781
• First Posted: Nov 1, 2009
• Last Update Posted: Aug 17, 2022
• Last Verified: Aug 1, 2022

• Keywords provided by H. Lee Moffitt Cancer Center and Research Institute: skin; adoptive cell therapy; tumor-infiltrating lymphocytes (TIL); lymphodepletion
• Additional relevant MeSH terms: Melanoma; Aldesleukin; Interleukin-2

Study Results

Participant Flow

Recruitment Details	Participants were recruited at Moffitt Cancer Center from October 20, 2009 until November 15, 2012.

Arm/Group Title	TIL With High Dose IL-2
Arm/Group Description	Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion. Surgery: Surgery to remove a tumor for growth of TIL Administration of Lymphodepletion: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo Adoptive Cell Transfer: T-cell infusion High Dose IL-2: Beginning approximately 12 - 16 hours after cell infusion.
Period Title: Overall Study
STARTED	19
COMPLETED	13
NOT COMPLETED	6

Baseline Characteristics

Arm/Group Title	TIL With High Dose IL-2
Arm/Group Description	Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion. Surgery: Surgery to remove a tumor for growth of TIL Administration of Lymphodepletion: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo Adoptive Cell Transfer: T-cell infusion High Dose IL-2: Beginning approximately 12 - 16 hours after cell infusion.
Overall Participants	19
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	46.5
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	15 78.9%
>=65 years	4 21.1%
Sex: Female, Male (Count of Participants)
Female	7 36.8%
Male	12 63.2%
Region of Enrollment (participants) [Number]
United States	19 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Tumor Infiltrating Lymphocytes (TIL) Growth
Description	Feasibility was the primary endpoint of this trial, defined as a patient who can grow and expand T-cells: Number of participants with fragments cultured; Number of participants with fragments that reached a final count of 20e6 cells within 5 weeks of culture; Number of participants with fragments that reached a final count of 20e6 cells within 5 weeks of culture and were cocultured with autologous or human leukocyte antigen (HLA)-matched tumor cells for interferon(IFN)-γ production; Number of participants with fragments that produced IFN-γ in response to autologous or HLA-matched tumor cells.
Time Frame	192 Days Post Surgical Resection

Outcome Measure Data

Analysis Population Description

All participants

Arm/Group Title	TIL With High Dose IL-2
Arm/Group Description	Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion. Surgery: Surgery to remove a tumor for growth of TIL Administration of Lymphodepletion: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo Adoptive Cell Transfer: T-cell infusion High Dose IL-2: Beginning approximately 12 - 16 hours after cell infusion.
Measure Participants	19
Participants with fragments cultured	19 100%
Participants with fragments grown	14 73.7%
Participants with fragments tested	14 73.7%
Participants with IFN-γ positive fragments	13 68.4%

2. Secondary Outcome

Title	Number of Participants With Objective Response (OR)
Description	OR is defined as the patient being alive at Day 70 and tumor size evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be a complete response or partial response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Evaluations were made by computed tomography (CT) scan approximately 6 to 8 weeks after the cell infusion, or CT scan approximately 10 weeks after the cell infusion, or by clinical evaluation during the first 70 days.
Time Frame	Average of 10 Months Follow-up

Outcome Measure Data

Analysis Population Description

All participants who completed treatment

Arm/Group Title	TIL With High Dose IL-2
Arm/Group Description	Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion. Surgery: Surgery to remove a tumor for growth of TIL Administration of Lymphodepletion: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo Adoptive Cell Transfer: T-cell infusion High Dose IL-2: Beginning approximately 12 - 16 hours after cell infusion.
Measure Participants	13
Partial Response (PR)	3 15.8%
Complete Response (CR)	2 10.5%
Complete Response (PR + CR)	5 26.3%

Adverse Events

Time Frame	3 years
Adverse Event Reporting Description	All participants
Arm/Group Title	TIL With High Dose IL-2
Arm/Group Description	Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours. Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days. Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused. Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion. Surgery: Surgery to remove a tumor for growth of TIL Administration of Lymphodepletion: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo Adoptive Cell Transfer: T-cell infusion High Dose IL-2: Beginning approximately 12 - 16 hours after cell infusion.
All Cause Mortality
	TIL With High Dose IL-2
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	TIL With High Dose IL-2
	Affected / at Risk (%)	# Events
Total	7/19 (36.8%)
Blood and lymphatic system disorders
Febrile neutropenia	1/19 (5.3%)	1
Cardiac disorders
Atrial fibrillation	1/19 (5.3%)	1
Ear and labyrinth disorders
Hearing impaired	1/19 (5.3%)	1
Eye disorders
Cataract	1/19 (5.3%)	1
Uveitis	1/19 (5.3%)	1
Gastrointestinal disorders
Constipation	1/19 (5.3%)	1
Nausea	2/19 (10.5%)	2
Vomiting	3/19 (15.8%)	3
General disorders
Fatigue	1/19 (5.3%)	1
Fever	1/19 (5.3%)	1
Infections and infestations
Bladder infection	1/19 (5.3%)	1
Investigations
Blood antidiuretic hormone abnormal	1/19 (5.3%)	1
Urine output decreased	1/19 (5.3%)	1
Metabolism and nutrition disorders
Dehydration	1/19 (5.3%)	1
Hyponatremia	1/19 (5.3%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other - basal cell carcinoma	1/19 (5.3%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Invasive squamous cell	1/19 (5.3%)	2
Renal and urinary disorders
Acute kidney injury	1/19 (5.3%)	1
Cystitis noninfective	1/19 (5.3%)	1
Respiratory, thoracic and mediastinal disorders
Hypoxia	1/19 (5.3%)	1
Pleural effusion	1/19 (5.3%)	1
Respiratory, thoracic and mediastinal disorders - Other - pulmonary edema	1/19 (5.3%)	1
Other (Not Including Serious) Adverse Events
	TIL With High Dose IL-2
	Affected / at Risk (%)	# Events
Total	14/19 (73.7%)
Blood and lymphatic system disorders
Anemia	13/19 (68.4%)	71
Febrile neutropenia	9/19 (47.4%)	9
Blood and lymphatic system disorders - Other	7/19 (36.8%)	24
Cardiac disorders
Sinus tachycardia	10/19 (52.6%)	14
Atrial fibrillation	3/19 (15.8%)	3
Cardiac disorders - Other	3/19 (15.8%)	4
Chest pain - cardiac	1/19 (5.3%)	1
Myocarditis	1/19 (5.3%)	1
Sinus bradycardia	1/19 (5.3%)	1
Supraventricular tachycardia	1/19 (5.3%)	1
Ear and labyrinth disorders
Ear and labyrinth disorders - Other	1/19 (5.3%)	1
Hearing impaired	1/19 (5.3%)	1
Tinnitus	1/19 (5.3%)	1
Vertigo	1/19 (5.3%)	1
Eye disorders
Blurred vision	2/19 (10.5%)	2
Flashing lights	2/19 (10.5%)	3
Cataract	1/19 (5.3%)	1
Photophobia	1/19 (5.3%)	1
Uveitis	1/19 (5.3%)	1
Gastrointestinal disorders
General disorders and administration site - Other	3/19 (15.8%)	4
Nausea	13/19 (68.4%)	19
Vomiting	10/19 (52.6%)	15
Diarrhea	9/19 (47.4%)	12
Constipation	3/19 (15.8%)	5
Mucositis oral	3/19 (15.8%)	4
Abdominal pain	1/19 (5.3%)	1
Anal hemorrhage	1/19 (5.3%)	1
Dysphagia	1/19 (5.3%)	1
Gastroparesis	1/19 (5.3%)	1
General disorders
Fatigue	14/19 (73.7%)	32
Chills	13/19 (68.4%)	17
Edema - limbs	5/19 (26.3%)	9
Pain	3/19 (15.8%)	3
Fever	2/19 (10.5%)	3
Edema - trunk	1/19 (5.3%)	1
Immune system disorders
Cytokine release syndrome	3/19 (15.8%)	3
Immune system disorders - Other	3/19 (15.8%)	4
Infections and infestations
Bladder infection	1/19 (5.3%)	1
Skin infection	1/19 (5.3%)	3
Investigations
Platelet count decreased	13/19 (68.4%)	84
White blood cell decreased	13/19 (68.4%)	52
Alkaline phosphatase increased	10/19 (52.6%)	19
Blood bilirubin increased	10/19 (52.6%)	23
Alanine aminotransferase increased	8/19 (42.1%)	11
Creatinine increased	8/19 (42.1%)	13
Lymphocyte count decreased	8/19 (42.1%)	27
Aspartate aminotransferase increased	7/19 (36.8%)	12
Neutrophil count decreased	7/19 (36.8%)	22
Activated partial thromboplastin time prolonged	1/19 (5.3%)	1
Blood antidiuretic hormone abnormal	1/19 (5.3%)	1
Investigations - Other	1/19 (5.3%)	1
Urine output decreased	1/19 (5.3%)	1
Metabolism and nutrition disorders
Hyponatremia	13/19 (68.4%)	29
Hypocalcemia	12/19 (63.2%)	43
Hypophosphatemia	12/19 (63.2%)	23
Anorexia	10/19 (52.6%)	13
Hypoalbuminemia	10/19 (52.6%)	42
Hyperglycemia	9/19 (47.4%)	25
Hypomagnesemia	9/19 (47.4%)	17
Hypokalemia	4/19 (21.1%)	7
Hypermagnesemia	3/19 (15.8%)	3
Hypoglycemia	3/19 (15.8%)	5
Hyperkalemia	2/19 (10.5%)	2
Hypernatremia	2/19 (10.5%)	2
Acidosis	1/19 (5.3%)	1
Dehydration	1/19 (5.3%)	1
Musculoskeletal and connective tissue disorders
Back Pain	2/19 (10.5%)	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other	2/19 (10.5%)	2
Nervous system disorders
Headache	5/19 (26.3%)	7
Dizziness	2/19 (10.5%)	2
Cognitive disturbance	1/19 (5.3%)	1
Depressed level of consciousness	1/19 (5.3%)	1
Dysgeusia	1/19 (5.3%)	1
Encephalopathy	1/19 (5.3%)	1
Sinus pain	1/19 (5.3%)	1
Syncope	1/19 (5.3%)	1
Vasovagal reaction	1/19 (5.3%)	1
Psychiatric disorders
Confusion	4/19 (21.1%)	6
Anxiety	3/19 (15.8%)	3
Insomnia	3/19 (15.8%)	3
Depression	2/19 (10.5%)	2
Delirium	1/19 (5.3%)	3
Renal and urinary disorders
Acute kidney injury	3/19 (15.8%)	8
Urinary retention	3/19 (15.8%)	3
Proteinuria	2/19 (10.5%)	2
Bladder spasm	1/19 (5.3%)	1
Cystitis noninfective	1/19 (5.3%)	1
Hematuria	1/19 (5.3%)	3
Renal and urinary disorders - Other	1/19 (5.3%)	2
Urinary frequency	1/19 (5.3%)	1
Urinary incontinence	1/19 (5.3%)	1
Urinary tract pain	1/19 (5.3%)	2
Urine discoloration	1/19 (5.3%)	2
Respiratory, thoracic and mediastinal disorders
Dyspnea	9/19 (47.4%)	10
Hypoxia	5/19 (26.3%)	5
Pleural effusion	4/19 (21.1%)	5
Respiratory, thoracic and mediastinal disorders - Other	4/19 (21.1%)	4
Epistaxis	3/19 (15.8%)	3
Hiccups	3/19 (15.8%)	3
Pulmonary edema	3/19 (15.8%)	3
Cough	2/19 (10.5%)	2
Adult respiratory distress syndrome	1/19 (5.3%)	1
Allergic rhinitis	1/19 (5.3%)	1
Bronchospasm	1/19 (5.3%)	1
Laryngeal edema	1/19 (5.3%)	1
Pneumonitis	1/19 (5.3%)	1
Sore throat	1/19 (5.3%)	1
Skin and subcutaneous tissue disorders
Alopecia	6/19 (31.6%)	6
Rash maculo-papular	5/19 (26.3%)	5
Pruritus	3/19 (15.8%)	3
Skin and subcutaneous tissue disorders - Other	3/19 (15.8%)	4
Dry skin	2/19 (10.5%)	2
Hyperhidrosis	1/19 (5.3%)	1
Vascular disorders
Hypotension	9/19 (47.4%)	9
Capillary leak syndrome	4/19 (21.1%)	4
Vascular disorders - Other	4/19 (21.1%)	5
Flushing	2/19 (10.5%)	2
Hot flashes	2/19 (10.5%)	2
Hypertension	1/19 (5.3%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.